top of page
Sage Group News
Opportunity for Leadership in Epigenetic Control of Metastatic Cancer
Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of...
OraMelts Drug Delivery Platform: Opportunity for Leadership in IntraOral Drug Delivery
The Sage Group is representing Quest Consumer Health Holdings, the owner of the OraMelts manufacturing facility and patent portfolio, in...
The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT®
The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT® 7 Year Agreement with medac to Maximize Potential of...
Opportunity to Partner OncoSec: a Novel Immunotherapy Company
10 December 2018 - New York and London - The Sage Group is pleased to announce that it is working with OncoSec, an American corporation,...
ASIT biotech initiates the search for a strategic commercial partner for the future marketing of gp-
• The Sage Group, an internationally recognized consulting group, has been appointed to identify a commercial partner with a special...
Moberg's BUPIZENGE™ - Sage Group Offers An Opportunity for Leadership in Pain Relief for Oral Mu
Stockholm, Sweden, 8 September 2018 – Moberg has appointed The Sage Group to lead the BUPIZENGE™ partnering program. Moberg Pharma is a...
Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio
Sage Group is working with Solvotrin Therapeutics (“Solvotrin”), based in Cork, Ireland. Solvotrin is a drug development company focused...
Anapa Biotech Announces The Launch of Its Groundbreaking MeltPlex® Technology for Multiplexed Nuclei
Copenhagen, Denmark, 2 August 2018 – Anapa Biotech (“Anapa”; www.meltplex.com) is a Copenhagen - based company with novel intellectual...
bottom of page